MX393992B - Compuestos de aminotiazol como inhibidores de la proteina quinasa - Google Patents

Compuestos de aminotiazol como inhibidores de la proteina quinasa

Info

Publication number
MX393992B
MX393992B MX2019014845A MX2019014845A MX393992B MX 393992 B MX393992 B MX 393992B MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 393992 B MX393992 B MX 393992B
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
aminothiazole compounds
compounds
aminothiazole
Prior art date
Application number
MX2019014845A
Other languages
English (en)
Other versions
MX2019014845A (es
Inventor
Chuan Shih
Hiu-jen TSAI
Weir-Torn Jiaang
Original Assignee
Chuan Shih
National Health Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuan Shih, National Health Res Inst filed Critical Chuan Shih
Publication of MX2019014845A publication Critical patent/MX2019014845A/es
Publication of MX393992B publication Critical patent/MX393992B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de aminotiazol de la Fórmula (I) que se muestran a continuación y las composiciones farmacéuticas que contienen uno de tales compuestos: (ver Fórmula) También se describen métodos para inhibir una tirosina quinasa y tratar el cáncer asociado con una tirosina quinasa con uno de los compuestos de aminotiazol.
MX2019014845A 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa MX393992B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2019014845A MX2019014845A (es) 2020-08-06
MX393992B true MX393992B (es) 2025-03-24

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014845A MX393992B (es) 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa

Country Status (13)

Country Link
US (1) US10300061B2 (es)
EP (1) EP3638237B1 (es)
JP (1) JP6979595B2 (es)
KR (1) KR102372288B1 (es)
CN (1) CN110831596B (es)
AU (1) AU2018284249B2 (es)
CA (1) CA3064081C (es)
ES (1) ES2949616T3 (es)
MX (1) MX393992B (es)
MY (1) MY201291A (es)
TW (1) TWI667236B (es)
WO (1) WO2018231910A1 (es)
ZA (1) ZA202000107B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
JP7681018B2 (ja) * 2019-11-14 2025-05-21 エーツーエー ファーマシューティカルズ インコーポレーテッド 抗がん剤としてｔａｃｃ３を標的とするイソオキサゾール誘導体
EP4087574A4 (en) * 2020-03-06 2024-01-17 National Health Research Institutes PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2006231929B2 (en) * 2005-04-04 2012-09-06 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
EP2736904B1 (en) * 2011-07-27 2016-03-16 AB Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
EP3638237A1 (en) 2020-04-22
KR20200014350A (ko) 2020-02-10
WO2018231910A1 (en) 2018-12-20
EP3638237B1 (en) 2023-04-19
AU2018284249B2 (en) 2021-06-24
CA3064081A1 (en) 2018-12-20
AU2018284249A1 (en) 2019-12-12
JP6979595B2 (ja) 2021-12-15
TW201906836A (zh) 2019-02-16
CN110831596A (zh) 2020-02-21
CA3064081C (en) 2023-03-21
ES2949616T3 (es) 2023-10-02
RU2019137573A3 (es) 2021-07-23
TWI667236B (zh) 2019-08-01
US20180353509A1 (en) 2018-12-13
NZ759327A (en) 2021-08-27
CN110831596B (zh) 2025-01-24
BR112019026577A8 (pt) 2023-04-11
BR112019026577A2 (pt) 2020-06-23
ZA202000107B (en) 2020-12-23
MY201291A (en) 2024-02-15
KR102372288B1 (ko) 2022-03-08
RU2019137573A (ru) 2021-05-24
MX2019014845A (es) 2020-08-06
EP3638237A4 (en) 2021-01-13
JP2020523348A (ja) 2020-08-06
US10300061B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
ZA202401324B (en) Tyrosine kinase inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MY210070A (en) Heterocyclic compounds as immunomodulators
MX393992B (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MY194262A (en) Inhibitors of ret
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EA201691916A1 (ru) Биарильные ингибиторы киназы
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MX2018008362A (es) Derivados de quinolin-2-ona.
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.